Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004 following multiple dose administration over 14 days.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim